A study of TY-9591 for lung cancer that has spread to the brain

Official title: TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on August 25, 2026.

The short version

This study tests a drug called TY-9591 in people whose lung cancer has spread to the brain.

What the trial team says

This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number: NCT05948813
Stage of testing: Phase 2
Conditions studied: NSCLC, EGFR Activating Mutation, Brain Metastases

Where it is running

This trial lists 1 site.

Beijing Municipality
- National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing)

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.